Nuvation Bio Inc.
Nuvation Bio Inc. is a U.S.-based oncology company focused on developing small-molecule cancer therapies and drug candidates for patients with difficult-to-treat tumors. The company’s pipeline includes clinical-stage and preclinical programs, and it operates through a mix of internal development and collaborations with partners in selected territories.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved or near-commercial cancer therapies such as taletrectinib and related licensed products.
Drug candidates in clinical development, including safusidenib and NUV-1511.
Earlier-stage small-molecule oncology assets being discovered or optimized internally.
Partnered development, territorial rights, and revenue-sharing structures tied to pipeline assets.
Products
Reported · share of revenue- License60.8 %
- Products39.2 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Nuvation Bio’s direct customers are primarily healthcare and pharmaceutical channel participants that purchase or distribute oncology products once approved, rather than end patients. Its broader economic customers also include licensing and development partners that obtain territorial rights to advance product candidates in specific markets. The company’s pipeline is ultimately aimed at oncologists, hospitals, cancer centers, and specialty pharmacies serving patients with targeted cancer indications.
Buy approved oncology products for downstream dispensing and reimbursement workflows.
Use targeted cancer therapies in clinical practice for specific tumor subtypes.
Acquire territorial rights to develop and commercialize pipeline assets.
Influence adoption by selecting therapies for biomarker-defined patient groups.
Strategy
The company’s strategy is to advance validated oncology targets into differentiated small-molecule therapies with the goal of improving efficacy and tolerability versus existing drugs. It also seeks to use partnerships and in-licensing to extend reach into markets where it does not commercialize directly, while continuing internal discovery and clinical development. This approach is designed to combine scientific focus with optionality across development, approval, and commercialization pathways.
Near-term value depends on converting a late-stage ROS1 program into a marketed product.
Pipeline breadth reduces dependence on a single asset and expands future indications.
Partners can accelerate access in markets where the company lacks direct infrastructure.
New assets are needed to sustain long-term oncology growth beyond current candidates.
Geography
Q1/2026Nuvation Bio is headquartered in the United States but describes itself as a global oncology company, with development and commercialization activities spanning multiple regions. The company has disclosed foreign regulatory exposure across Europe, the U.K., and China, and it also acquired AnHeart Therapeutics, a Cayman Islands entity, to expand its pipeline and international footprint. Geography matters because regulatory approval, commercialization rights, and partner execution can differ by territory and directly affect where products can be launched.
Share of the revenue the company reports by geography.
Risks
Nuvation Bio is highly dependent on successful clinical development, regulatory approvals, and commercialization of a small number of oncology assets. As a development-stage biotech, it also faces substantial funding needs, partner execution risk, and the possibility that approved products may not achieve sufficient market adoption. Regulatory, manufacturing, and safety issues can delay or prevent revenue generation and materially affect the business.
- Clinical development failureImpact: HighLikelihood: High
Pipeline candidates may not show sufficient efficacy or safety in trials.
Exposure - Regulatory approval riskImpact: HighLikelihood: High
FDA, EMA, MHRA, and NMPA approvals are required before marketing.
Exposure - Capital raising and dilution riskImpact: HighLikelihood: High
The company needs substantial funding before product sales are meaningful.
Exposure - Dependence on taletrectinib commercializationImpact: HighLikelihood: Medium
Near-term revenue and valuation are tied to one late-stage oncology product.
Exposure: IBTROZI/taletrectinib
- Partner commercialization riskImpact: MediumLikelihood: Low
Ex-U.S. revenue depends partly on collaborators executing effectively.
Exposure: territorial partners
Accounting
Judgemental itemsChargebacks, rebates, returns, and discounts require estimates that affect net sales.
Impact: Can materially change reported product revenue period to period
Partnered development and territorial rights may require allocation of consideration.
Impact: Affects timing and classification of revenue
Recent borrowings and revenue-interest financing create non-operating accounting complexity.
Impact: Influences interest expense and balance sheet presentation
Clinical and regulatory setbacks can reduce the value of capitalized or acquired programs.
Impact: May trigger write-downs or valuation adjustments
Similar listed companies
Publicly listed companies with a comparable business focus.
Nuvalent, Inc.
Pharmaceutical Preparations
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
NovaBridge Biosciences
NBP · Pharmaceutical Preparations
NovaBridge Biosciences is a global biotechnology company focused on discovering, developing, and partnering around differentiated therapeutic candidates in oncology and ophthalmology.
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
BridgeBio Oncology Therapeutics, Inc.
BBOT · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026